HAT1

DRUG2 trials

Sponsors

Haus Bioceuticals

Conditions

Atopic DermatitisHealthyPsoriasis

Phase 2

Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis

CompletedNCT03848806

Haus BioceuticalsPsoriasis

Start: 2016-02-29End: 2016-09-05Updated: 2019-02-21

Phase 4

A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests

CompletedNCT03406117

Haus BioceuticalsAtopic Dermatitis, Healthy, Psoriasis

Start: 2016-04-01End: 2016-07-21Updated: 2018-11-06